Tim Watkins, serving as the Chief Medical Officer and Head of Development at Contineum Therapeutics, Inc. (NASDAQ:CTNM), finalized a sequence of equity transactions on June 30, 2026. The filings indicate the sale of 10,833 shares of the company's Class A Common Stock, generating a total transaction value of $173,590. The execution price for these shares averaged $16.0242, with individual sale prices recorded between $16.00 and $16.15.
These sales occurred against a backdrop of substantial recent price appreciation for CTNM. The stock has experienced a surge of nearly 296% over the trailing twelve months and posted a 19% gain within the preceding week, trading close to its 52-week high of $16.91. The timing of the sale coincides with this period of elevated valuation.
Concurrently with the sale, Watkins exercised stock options to acquire an identical quantity of 10,833 shares. The exercise price for these options was established at $4.50 per share, resulting in a total cost of $48,748. Both the acquisition and the subsequent disposition were executed under a pre-arranged 10b5-1 trading plan. Watkins originally adopted this plan on September 23, 2025, which dictates the timing and execution of these transactions independent of current market conditions or internal information.
The specific stock options exercised carry a conversion price of $4.50 per share and are scheduled to expire on April 27, 2035. The vesting schedule for these options required one-half to vest on October 28, 2025, with the remaining portion vesting in 36 equal monthly installments, contingent upon Watkins maintaining continuous service with the company.
Following the completion of these transactions, Watkins' direct holdings in Contineum Therapeutics Class A Common Stock stand at 8,961 shares. This figure includes shares acquired through the company's Employee Stock Purchase Plan. In addition to his direct equity, Watkins retains a position of 238,334 stock options. According to InvestingPro analysis, the stock currently appears overvalued relative to its calculated Fair Value, a metric that may provide context for the decision to reduce direct holdings during this period. The company maintains a "GOOD" financial health score, and InvestingPro offers 13 additional exclusive tips for CTNM investors.
Contineum Therapeutics has recently drawn attention for advancements in its clinical pipeline, specifically regarding the drug candidate PIPE-791. The company announced the publication of a manuscript in the Journal of Medicinal Chemistry detailing the discovery and characterization of this compound. PIPE-791 is identified as a lysophosphatidic acid receptor 1 (LPAR1) antagonist designed to treat fibrotic conditions. Its chemical structure is noted for enabling slow on-off binding rates, which facilitates sustained target coverage.
Additionally, Contineum reported topline data from a phase 1b trial of PIPE-791 targeting chronic osteoarthritis pain and chronic low back pain. The trial was a randomized, double-blind, placebo-controlled study involving 43 patients. The protocol tested the oral administration of PIPE-791 at a dosage of 10mg once daily over a four-week crossover period. These developments underscore the company's ongoing efforts to advance its drug pipeline and validate its therapeutic candidates.